Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

about

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Item

http://www.wikidata.org/entity/Q55285379

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@en

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@nl

type

Item

label

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@en

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@nl

altLabel

Parkinson's Patients with Dysk ...... ntadine to Open‐label ADS‐5102

@en

prefLabel

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@en

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@nl

P1476

Parkinson's Patients with Dysk ...... tadine to Open-label ADS-5102.

@en

P2093

Rajiv Patni

http://www.w3.org/2001/XMLSchema#string

Reed Johnson

http://www.w3.org/2001/XMLSchema#string

Stuart H Isaacson

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Pharmacological treatment of Parkinson disease: a review.

The scientific and clinical basis for the treatment of Parkinson disease (2009).

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

P304

183-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDC3.12595

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29780852

http://www.w3.org/2001/XMLSchema#string

P932

5947645

http://www.w3.org/2001/XMLSchema#string